Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended								12 Months Ended
		Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2017		Jun. 30, 2016		Jun. 30, 2015
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue		$ 616.9	$ 532.6	$ 483.7	$ 442.2	$ 532.2	$ 438.0	$ 454.9	$ 423.0	$ 2,075.4		$ 1,848.1		$ 1,830.8
Segment EBITDA										372.2		374.3		360.2
Inter-segment revenue elimination										(38.8)		(40.8)		(43.4)
Impairment charges and gain/(loss) on sale of assets										(9.8)		(2.7)		(4.7)
Equity compensation										(20.9)		(10.8)		(9.0)
Restructuring and other special items	[1]									(33.5)		(27.2)		(27.2)
Net Income (Loss) Attributable to Noncontrolling Interest										0.0		0.3		1.9
Other income (expense), net	[2]									(8.5)		15.6		(42.4)
Non-allocated corporate costs, net										(42.9)		(33.1)		(19.4)
Total unallocated costs										(115.6)	[3]	(57.9)	[4]	(100.8)	[3]
Gain (Loss) on Contract Termination										0.0		0.0		29.8	[5]
Extinguishment of Debt, Gain (Loss), Net of Tax												0.0		(21.8)
Business Combination, Gain Recognized on Bargain Purchase plus Gain/(Loss) from Change in Redeemable Noncontrolling Interest										0.0		0.0		8.9	[4]
Softgel Technologies [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue										855.3		775.0		787.5
Segment EBITDA										190.5		163.8		173.6
Drug Delivery Solutions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue										910.1		806.4		798.3
Segment EBITDA										242.4		215.2		230.7
Clinical Supply Services [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue										348.8		307.5		288.4
Segment EBITDA										$ 54.9		$ 53.2		$ 56.7

[1] Segment results do not include restructuring and certain acquisition-related costs

[2] Refer to Note 13 for details.

[3] Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows

[4] Included within Other (income) / expense, net are gains associated with acquisitions completed during the respective periods. Such income events are non-standard in nature and not reflective of the Company’s core operating results. During the twelve months ended June 30, 2015, the Company recorded a gain of $3.2 million on the re-measurement of a cost investment in an entity that became a wholly owned subsidiary as of October 2014, a $7.0 million bargain purchase gain for an acquisition completed in July 2014, and a $1.3 million loss on a redeemable noncontrolling interest in June 2015.

[5] The Company paid a sponsor advisory agreement termination fee of $29.8 million in connection with its IPO.